From GlobeNewswire:

Altamira Therapeutics is presenting at the 3rd Annual mRNA-Based Therapeutics Summit on January 23-25 at the JW Marriott Hotel in Berlin. COO Dr. Covadonga Pañeda will present on the delivery of therapeutic RNA in inflammation and cancer, highlighting Altamira’s SemaPhore platform for efficient and safe mRNA delivery to non-hepatic tissues. The peptide-based platform has been successfully tested in models of osteoarthritis, atherosclerosis, aortic aneurysm, and the tumor microenvironment. Altamira Therapeutics, listed on the Nasdaq as CYTO, is developing siRNA programs for KRAS-driven cancer and rheumatoid arthritis, along with a nasal spray for allergic rhinitis. Their legacy assets, including projects focused on vertigo, tinnitus, and hearing loss, are being considered for partnering or divesting. Investors are cautioned regarding forward-looking statements.



Read more: Altamira Therapeutics to Present at 3rd Annual mRNA-Based